OraPharma Introduces ARESTIN® Student Access Program

Program Provides Dental & Hygiene Schools with Access to Product and Educational Resources
Posted: August 10, 2007

OraPharma Introduces ARESTIN® Student Access Program
 
Program Provides Dental & Hygiene Schools with Access to Product and Educational Resources that Enable Hands-On Training for Periodontal Disease Treatment Using Locally Administered Antibiotics
 
Warminster, PA – August 07, 2007 – OraPharma, Inc. is a cutting-edge specialty oral health care company dedicated to bringing scientifically and technologically advanced products and services to the dental community, as well as providing educational support and training to the dental community. In keeping with this mission, OraPharma, Inc., maker of ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, recently introduced the ARESTIN® Student Access Program for dental and hygiene schools.
 
According to ARESTIN® Product Director John Lenart, “We have been working closely with the directors of leading dental and hygiene schools for several years to develop a program that will provide educational programming and hands-on training so that senior dental and hygiene students can appropriately incorporate locally administered antibiotics like ARESTIN® as part of a comprehensive periodontal disease treatment protocol.” 
 
The program, which is scheduled to begin in September 2007, is open to all accredited two- or four-year dental and dental hygiene schools that include instruction on the use of ARESTIN® as part of a comprehensive Periodontal Treatment Protocol. Participating dental and hygiene schools will receive the following ARESTIN® Student Access Program materials:
 
·         One ARESTIN® Trial Kit containing 12 ARESTIN® cartridges for clinical use by each participating senior student
·         Two free ARESTIN® handles per school for program instructors 
·         One Instructor Education Kit containing valuable clinical and patient resources regarding periodontal therapy and ARESTIN®, as well as educational content easily added to classroom lectures
·         Student Education Kits including valuable clinical and patient education resources regarding periodontal therapy and ARESTIN®, as well as a complimentary ARESTIN®- branded Hu-Friedy Colorvue® periodontal probe, and one package of ARESTIN® demonstration product
·         The ability to order discounted ARESTIN® handles for all participating senior students
·         Sample patient treatment log and performance check sheet to track the placement and results of periodontal therapy with scaling and root planing (SRP) + ARESTIN®
 
“The launch of the ARESTIN® Student Access Program marks the first time that ARESTIN® will be widely available for clinical use by all dental and hygiene school students. The next generation of oral health professionals who are able to participate in this program will have a better understanding of the latest periodontal disease treatments available and, in turn, be better prepared to treat patients they will soon see upon graduation,” said Lenart.
 
Dental and hygiene school faculty who wish to participate in the ARESTIN® Student Access Program or require more information are invited to contact the ARESTIN® Team at 800-553-6010 ext. 0747.
 
About OraPharma, Inc.
 
OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. OSSIX® PLUS (resorbable collagen membrane) is used in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures. For more information about OraPharma and its products, visit http://www.orapharma.com
  
  
 
ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is indicated as an adjunct to
scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which
includes good oral hygiene, and scaling and root planing.
 
ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.
 
The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.
 
 
Views: 61
Sponsors
Sally Gross, Member Services Specialist
Phone: +1-480-445-9710
Email: sally@farranmedia.com
©2025 Hygienetown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450